Physician profile
Mitchell Seidman
NPI 1013999697
$1,077.76
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $19.49 · 2022: $45.11.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $507.40 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $245.56 | 2019 | |
| Eyepoint US, INC. | $173.12 | 2019 | |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Sun Pharmaceutical Industries INC. | $29.53 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.50 | 2022 | |
| Oyster Point Pharma, INC. | $21.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.49 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Seidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.